Research Article
Treatment of Glucocorticoid-Induced Osteoporosis and Risk Factors for New Vertebral Fractures in Female Patients with Autoimmune Diseases
Table 4
Comparison of patient characteristics in patients who received bisphosphonate treatments with and without new vertebral fractures.
| | | Without fracture (n = 24) | With fracture (n = 6) | value (t-test) | Unadjusted OR (95% CI) | p value (logistic regression) |
| | Age, (years) | 56 (13.1) | 63 (12.4) | 0.25 | 1.05 (0.97-1.14) | 0.215 | | Disease duration (years), mean (SE) | 9.5 (7.8) | 15 (13.4) | 0.19 | 1.07 (0.97-1.17) | 0.189 | | Max. glucocorticoid dose (mg) | 33.1 (17.7) | 34 (18.8) | 0.90 | 1.003 (0.95-1.06) | 0.895 | | Current glucocorticoid dose (mg) | 6.3 (2.7) | 9.3 (3.2) | 0.02 | 1.45 (1.02-2.07) | 0.022 | | Combined vitamin D3, no. (%) | 19 (79.2) | 1 (16.7) | 0.0037 | 19 (1.79-201.68) | 0.015 | | Prior fragility fracture, no. (%) | 0 (0) | 1 (16.7) | 0.0419 | NA | NA |
| | BMD, % YAM | | Lumbar spine | 93.0 (2.4) | 84.3 (5.6) | 0.10 | 0.93 (0.85-1.012) | 0.076 | | Femoral neck | 85.6 (13.3) | 83.2 (5.2) | 0.67 | 0.98 (0.91-1.06) | 0.66 |
| | Glucocorticoid-induced osteoporosis score | | Lumbar spine | 4.3 (1.8) | 7.8 (2.3) | 0.0006 | 2.15 (1.18-3.92) | 0.001 | | Femoral neck | 5.0 (2.2) | 7.5 (2.1) | 0.0213 | 1.54 (1.01-2.34) | 0.027 |
|
|
Data are presented as mean (SD) unless otherwise stated. BMD, bone mineral density; D3, active vitamin D3; YAM, young adult mean.
|
